MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
ARTV — Artiva Biotherapeutics, Inc. Common Stock
NasdaqArtiva Biotherapeutics, Inc. Common Stock
$6.83
+0.04(+0.59%)
- O
- 6.89
- H
- 7.00
- L
- 6.74
- V
- 587.44K
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About ARTV
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateJul 19, 2024
Employees115
Stock ExchangeNasdaq
Ticker SymbolARTV
Websitehttps://www.artivabio.com
Key Financial Statistics
| Market Cap | $341.74M |
| P/E Ratio | N/A |
| Dividend Yield | N/A |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $1.47 - $17.31 |
| 52-Week Avg Volume | 572.1K |
| VWAP | $6.85 |
| Transactions | 7,634 |
| Total Recorded Bars | 554 days |